Literature DB >> 3519482

Cephalosporins in cutaneous infections. A prospective comparison of two dosage regimens of ceftazidime for therapy of skin and skin structure infections.

L C Parish, J A Witkowski, R Snow, L Eron, W J Mogabgab.   

Abstract

The safety and efficacy of ceftazidime administered as 0.5 g every 8 hours (q8h) or 1.0 g q8h for at least 5 days were compared in 197 patients and found to be effective in the treatment of cellulitis, abscesses, skin ulcers, and wound infections. Staphylococcus aureus was the predominant pathogen in both treatment groups with approximately half of the isolates from each treatment group being gram-positive. Pseudomonas aeruginosa was the most common gram-negative isolate. P. aeruginosa, Proteus mirabilis, and Escherichia coli each comprised 5-12% of the isolates from each treatment group. Clinical cure or improvement was achieved in 98.7% of the patients in each treatment group. Concurrently with clinically successful treatment, a high rate of bacteriologic eradication without superinfection was achieved with the 0.5-g regimen (84% of all isolates) and the 1.0-g regimen (92%).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3519482     DOI: 10.1111/j.1365-4362.1986.tb02239.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  3 in total

1.  Bacterial infections of the skin treated with ciprofloxacin.

Authors:  A Gorkiewicz-Petkow; H Weuta; S Jablonska; L Petkow; S Bielunska; M Gawkonska
Journal:  Infection       Date:  1988       Impact factor: 3.553

2.  A multicentre, randomized comparative study of 500 mg versus 1,000 mg ceftazidime t.d.s. for treatment on gram-negative infections.

Authors:  H Mattie; M W Kunst; H I Schievink; P L Jonker; P de Jonge
Journal:  Infection       Date:  1995 Jul-Aug       Impact factor: 3.553

Review 3.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.